A decision aid for considering indomethacin prophylaxis vs. symptomatic treatment of PDA for extreme low birth weight infants by AlFaleh, Khalid M et al.
RESEARCH ARTICLE Open Access
A decision aid for considering indomethacin
prophylaxis vs. symptomatic treatment of PDA for
extreme low birth weight infants
Khalid M AlFaleh
1*, Eman Al Luwaimi
1, Turki M AlKharfi
1 and Saleh A Al-Alaiyan
2
Abstract
Background: Decision Aids (DA) are well established in various fields of medicine. It can improve the quality of
decision-making and reduce decisional conflict. In neonatal care, and due to scientific equipoise, neonatologists
caring for extreme low birth weight (ELBW) infants are in need to elicit parents’ preferences with regard to the use
of indomethacin therapy in ELBW infants. We aimed to develop a DA that elicits parents’ preferences with regard
to indomethacin therapy in ELBW infants.
Methods: We developed a DA for the use of the indomethacin therapy in ELBW infants according to the Ottawa
Decision Support Framework. The development process involved parents, neonatologists, DA developers and
decision making experts. A pilot testing with healthy volunteers was conducted through an evaluation
questionnaire, a knowledge scale, and a validated decisional conflict scale.
Results: The DA is a computer-based interactive tool. In the first part, the DA provides information about patent
ductus arteriosus (PDA) as a disease, the different treatment options, and the benefits and downsides of using
indomethacin therapy in preterm infants. In the second part, it coaches the parent in the decision making process
through clarifying values and preferences. Volunteers rated 10 out of 13 items of the DA positively and showed
significant improvement on both the knowledge scale (p = 0.008) and the decisional conflict scale (p = 0.008).
Conclusion: We have developed a computer based DA to assess parental preferences with regard to
indomethacin therapy in preterm infants. Future research will involve measurement of parental preferences to
guide and augment the clinical decisions in current neonatal practice.
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Background
Burden of Illness
Due to its high rate of mortality and morbidity, prema-
turity is by far the most important issue in modern peri-
natal medicine. Patent ductus arteriosus (PDA) is very
common among very low birth weight infants (VLBW),
the delay in closure of the ductus is inversely related to
gestational age varying from 20% in premature infants
greater than 32 weeks up to 60% in extreme low birth
weight infants (ELBW < 1000 g) [1,2]. PDA results in a
significant left to right shunt with an increase in left
ventricular output. Although it usually closes sponta-
neously by 5 days of age in most infants > 30 weeks’
gestation, it remains patent by 5 days of age in more
than two thirds of infants < 30 weeks [3].
Although controversial, observational data confirmed
an association of PDA with the subsequent development
of bronchopulmonary dysplasia (BPD) in premature
infants [4,5]. It has also been demonstrated that large
left to right shunting through the ductus results in a
diastolic steal of blood flow to vital organs i.e. brain,
kidneys, and intestines [6]. However, recent observa-
tional data failed to show an association of PDA with
necrotizing enterocolitis (NEC) [7]. Failure of the ductal
constriction has been shown to be associated with low
superior venacaval flow (SVC) and subsequent
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[8]. Lastly, large left to right ductal shunting is asso-
ciated with a significant increase in pulmonary blood
flow and serious pulmonary hemorrhage [9,10].
Indomethacin prophylaxis vs. treatment for symptomatic
PDA; the clinical dilemma
There is now a substantial body of literature available to
evaluate the role of indomethacin prophylaxis in the
management of the premature infant. Indomethacin
prophylaxis reduces the incidence of symptomatic PDA
by 55%, severe grade III and IV IVH by 35%, and the
need for surgical PDA ligation by 50% [11,12]. In addi-
tion a recent ancillary analysis on the database of the
trial of indomethacin prophylaxis in the preterm infants
(TIPP trial), showed a significant reduction of serious
clinically significant pulmonary hemorrhage during the
first week of life [13].
However, this significant reduction in symptomatic
PDA, severe IVH, and serious pulmonary hemorrhage
did not translate in reduction of mortality, BPD, and
more importantly the rates of long term neurosensory
outcome.
As a result of the data presented above, clinicians car-
ing for premature infants are left uncertain of what
would be the most sensible approach to the use of indo-
methacin prophylaxis in the preterm. Some clinicians
would justify its use based on the reduction of impor-
tant intermediate morbidities. On the other hand, others
would refrain employing a prophylactic strategy bearing
in mind the lack of long term improvement in mortality
rate and neurosensory outcome [14].
Patient decision aids can improve the quality of deci-
sion-making, reduce decisional conflict and help patients
become involved in decision making by providing infor-
mation about the options and outcomes and by clarify-
ing personal values. They are designed to complement,
rather than replace, counseling from a health practi-
tioner. The medical literature has observed an increasing
number and utilization of decision aids in patients man-
agement in various fields of medicine [15-17].
Objective
To develop a decision aid to elicit parents of premature
infants’ preferences with regard to indomethacin pro-
phylaxis vs. symptomatic treatment in the management
of their infants.
Methods
Structural development
The framework is an evidence-based, practical, midrange
theory for guiding parents making health or social deci-
sions. It follows the Ottawa Decision Support Frame-
work, and is based on the Ottawa Personal Decision
Guide (OPDG) [18]. The DA supports decision making
through providing information about the disorder, its
management and its outcomes through a computer
based interface.
Evidence Sources
Information about the outcomes of indomethacin pro-
phylaxis in ELBW infants were driven from the best evi-
dence reported in the published meta-analysis of
indomethacin prophylaxis use in preterm infants. More
than 19 randomized trials were included in the report
[11,12].
Platform design
A web-based DA format was chosen to allow for
broader utilization, easier access. A professional web
designing establishment developed the platform of the
DA using PHP scripting language and MySql database
and made available on the World Wide Web.
Experts’ feedback
Feedback of the DA structure and content was sought of
neonatologists, DA experts commenting on the struc-
ture and content of the DA. Eight experts were
approached by e-mail (5 international and 3 local).
Experts provided constructive feedback with some modi-
fication regarding the scientific data presented, language
and general layout of the DA.
Parents’ feedback
We conducted interviews with 10 expecting mothers
(ten mothers of infants in our NICU were randomly
selected to participate in this pilot study). Each partici-
pant answered specific questions and provided general
comments. An example of a general comment; “ it was
a simple and an interesting way to understand the con-
dition of my child, it is nice to see such interactive tools
to cover our health concerns about our children”. Modi-
fications were made based on the participant feedback.
Modifications were mainly related to the DA language,
numeric data presentation, and other scientific
information.
Pilot testing of the Decision Aid
Ten mothers (other than those involved in the parents
feedback) used the DA as if they were to make a real
life decision about the use of indomethacin therapy.
Initially, they were introduced to the concept of prema-
turity and PDA followed by explaining the role of indo-
methacin therapy as a management option. These
participants then completed 3 instruments: (1) an eva-
luation questionnaire; (2) a knowledge scale before and
after use; and (3) a validated decisional conflict scale
(before and after use) [18]. The evaluation questionnaire
addressed 9 features of the DA that participants rated
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value and 5 for lowest value). The knowledge scale con-
sisted of 8 questions we developed specifically about
prematurity, PDA, the required time and the need for
assistance in using the DA.
Statistical analysis
Tests utilized in this study were a one sample t-test for
the 5-point Likert scale and paired t-test to compare the
pre and post means for the knowledge and decisional
conflict scales. A two sided P value < 0.05 was consid-
ered statistically significant.
The study was approved by the ethics committee,
King Saud University, college of medicine, Riyadh, Saudi
Arabia.
Results
The Decision Aid (DA)
Structure
DA was structured in two parts; the first part provides
medical information about: the use of the DA, prema-
turity and its complications, PDA, and the use of indo-
methacin therapy in ELBW infants (prophylactic
indomethacin and symptomatic PDA treatment), chance
of intermediate outcomes (risk of PDA, surgical PDA
ligation, severe IVH), chance of long term outcomes
(survival, neurosensory impairment) for both options,
and potential adverse effects (gastrointestinal perfora-
tion, renal impairment) associated with indomethacin
prophylaxis use, all presented in a systematic and
balanced way through a series of screen shots, that
included several images and simplified language in both
paragraphs and bullet points.
In the second part; the DA coaches the parents in the
decision making process regarding the use of indo-
methacin for their preterm infants through: case scenar-
ios of the PDA and side effects of indomethacin,
clarification of the patient’s own values for each benefit
and harm; and assistance in the final decision making, a
verbal description of uncertainty was utilized (e.g. likely)
rather than a numeric one (e.g. 0.80) in order not to
overload participants with numbers and because evi-
dence shows that verbal is as effective as numeric com-
munication. However, numeric values were displayed on
the decision aid instrument [17].
Rating values
The parents will assign the value of each potential out-
come associated with indomethacin therapy. The DA
presents the values as a horizontal feeling-thermometer
with values ranging from 0 (worst outcome imaginable i.
e. death) to 100 (best health condition imaginable) by
increments of 1 unit. The parents move the cursor of the
scale to assign the value for a specific outcome. Their
assigned value will show in the box adjacent to the scale.
Decision making models
Later, the DA allows the parents to choose one of the
two possible decision making models. After integrating
the information provided, their values the parents will
provide a choice ‘’ to use ‘’ or ‘’ not to use’’ indometha-
cin as prophylaxis for their ELBW infant as an indivi-
dual choice. The parents have the choice to leave the
decision aid at any stage and leave the decision to their
health care provider.
Navigation
User friendly navigation was utilized. The parent can
access the first page of any section from any page of the
DA, and all pages of a particular section from any page
of that section.
Pilot testing of the Decision Aid
Characteristics of the mothers who participated in the
pilot testing of the DA are listed in Table 1.
The results of the pilot testing are listed in Table 2.
Positive feedback regarding the design, pictures, under-
standability, user friendliness, perceived required time,
explanations, and amount of information in the DA was
provided by the participants. They felt comfortable and
satisfied while using it. Both the knowledge and the
decisional conflict scales improved significantly after
review of the DA. The mean time needed to finish
reviewing the DA was 19 minutes, only one of the
volunteers needed assistance in using the appropriate
buttons to navigate the DA.
Discussion
We have developed a computer based interactive DA for
considering indomethacin therapy in the management of
ELBW infants following a detailed well structured meth-
odology based on the Ottawa Decision Support Frame-
work. The DA will help parents of ELBW infants have
an informed decision without the presence of their
health care provider with regard to whether to offer or
decline indomethacin prophylaxis in the management of
their infants. The DA will also augment further research
in evaluating parents preferences with regard to
Table 1 Baseline characteristics of pilot testing mothers
Variable Respondents (N = 10)
Mean
Age mean (SD) 36.2 (7.76)
Educational level N (%)
Less than high school 1(10)
High school 1 (10)
College 2 (10)
Graduate degree 6 (60)
Computer user 8 (80)
Internet user 8 (80)
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then completes the three circles (experience, research
evidence, and patient preferences) of evidence based
medicine in the area of indomethacin prophylaxis in
preterm infants. Parents evaluated our DA rated most of
its features positively and showed a significant improve-
ment in their knowledge, decisional conflict scales.
Our DA is the first to our knowledge in neonatal care;
it followed a rigorous well defined developmental pro-
cess, and offers the ease, accessibility and convenience
to users since it is web based. It can be utilized in the
care of preterm infants starting at the antenatal visit.
Our DA however has some limitations; first, our pilot
testing involved ten subjects that makes it difficult to
generalize the results for a wide spread use. Second, the
computer, web based design although advantageous to
many parents in the modern age makes it difficult to be
utilized by non computer users. Third, a limitations of
the DA development process is the lack of real life deci-
sion making of a parent of a preterm infant admitted in
the intensive care unit, our future research will involve
eliciting decision preferences of indomethacin therapy
including pregnant women, women at risk of preterm
delivery and parent of admitted extreme low birth
weight infants in neonatal intensive care unit to test the
impact of real life situation in the decision making
process.
These findings will be taken as a step for designing a
future project that involves evaluating parental prefer-
ences with regard to indomethacin therapy in ELBW
infants in a large representative sample to help guide
the practice of neonatal practitioners.
Conclusion
We have developed a computer based DA to assess par-
ental preferences with regard to indomethacin therapy
in preterm infants. Future research will involve measure-
ment of parental preferences to guide and augment the
clinical decisions in current neonatal practice.
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